Lakefront Biotherapeutics NV current report, Q1 FY2022

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV, a foreign private issuer, for the month of March 2022. The filing, dated March 24, 2022, incorporates by reference a press release issued on March 18, 2022 (Exhibit 99.1). The registrant is headquartered in Mechelen, Belgium, and files annual reports on Form 20-F.

Financial Metrics

The provided filing text does not contain specific financial data. It serves as a cover document to incorporate a press release by reference. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text.

Material Changes

The filing text does not disclose specific material changes to financial position or operations. It indicates that a material event or announcement was made via the attached press release, but the content of that announcement is not included in the provided text.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. It notes that the information in the attached press release is incorporated into various Registration Statements (Forms F-3 and S-8), but the substance of that information is absent from the source text.

Key Facts for Investor Verification

  • Verify the content of the press release dated March 18, 2022 (Exhibit 99.1), as the filing text only references it without summarizing its details.
  • Confirm the registrant's identity as Galapagos NV, noting the input metadata mentioned "Lakefront Biotherapeutics NV" which appears to be a discrepancy with the actual filing text.
  • Check the referenced Registration Statements (File Nos. 333-230639 and various S-8 filings) for the full context of the incorporated information.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.